The relationship between increased levels of microbiota-derived lipopolysaccharide in obesity and the pathophysiology of neurodegenerative diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review of proposed biological mechanisms without systematic methodology or primary human data.
PubMed 40683546 · doi:10.1016/j.micpath.2025.107905
What was done
The authors conducted a narrative review synthesizing biological mechanisms linking obesity-related gut microbiota alterations, intestinal barrier permeability, and circulating lipopolysaccharide (metabolic endotoxemia) to neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis.
What was found
The abstract provides no empirical quantitative data or numerical findings. It qualitatively details pathways through which lipopolysaccharide promotes persistent systemic inflammation, oxidative stress, microglial activation, and blood-brain barrier impairment, exacerbating protein misfolding, mitochondrial dysfunction, and neuronal apoptosis.
Why it matters
It highlights how metabolic endotoxemia derived from obesity-associated dysbiosis may serve as a shared mechanistic driver across multiple neurodegenerative disorders, framing gut barrier restoration as a potential therapeutic target.
Limits
This is a narrative review with no systematic literature search, quantitative effect sizes, or primary clinical data reported in the abstract. Causal links in human populations remain unquantified.
Cited by
- supports Elevated lipopolysaccharide (LPS) levels cause neurotoxicity or damage to the brain.